Related Experiment Video
Updated: May 5, 2026
Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis
Published on: February 8, 2017
Current preclinical models of brain metastasis
Zacharie Drouin1,2,3, Flavie Lévesque1,2,3, Korina Mouzakitis1,2,3
1Department of Immunology and Cell Biology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, 3201 Rue Jean-Mignault, Sherbrooke, QC, J1E 4K8, Canada.
Abstract:
Brain metastases (BMs) represent the most prevalent intracranial malignancy within the adult. They are identified in up to 20% of patients with solid tumors and this percentage varies between tumor types and age. Due to the selective permeability of the blood-brain barrier, most anticancer drugs can't reach significant concentrations in the brain, representing a major obstacle to the patients' survival. Furthermore, intra- and inter-patient heterogeneity and the unique brain microenvironment add a layer of complexity to the clinical management of BMs. In the perspective of finding new therapeutic approaches and better understanding the molecular mechanisms involved in brain metastasis, the use of appropriate preclinical models is essential. Here, we review current in vivo, in vitro and ex vivo models for the study of brain metastasis while outlining their advantages and limitations.
Insights
Brain metastases (BMs) are common in cancer patients. This review explores preclinical models to study BMs and overcome drug delivery challenges, aiding new therapeutic development.
Area of Science:
- Oncology
- Neuroscience
- Translational Medicine
Background:
- Brain metastases (BMs) are the most common brain tumors in adults, affecting up to 20% of cancer patients.
- The blood-brain barrier limits drug efficacy, posing a significant challenge for treating BMs.
- Tumor heterogeneity and the brain microenvironment complicate clinical management.
Purpose of the Study:
- To review existing preclinical models for studying brain metastasis.
- To outline the advantages and limitations of various in vivo, in vitro, and ex vivo models.
- To support the development of novel therapeutic strategies for BMs.
Main Methods:
- Comprehensive literature review of preclinical models for brain metastasis research.
- Analysis of in vivo (animal), in vitro (cell culture), and ex vivo (tissue explant) models.
- Evaluation of model suitability for investigating drug delivery and therapeutic efficacy.
Main Results:
- Various preclinical models exist, each with unique strengths and weaknesses for studying BMs.
- Models differ in their ability to recapitulate the complexities of human brain metastasis.
- No single model perfectly replicates the human condition, necessitating careful selection.
Conclusions:
- Appropriate preclinical models are crucial for advancing brain metastasis research.
- Understanding model limitations is key to interpreting results and developing effective treatments.
- Further development of sophisticated models is needed to improve patient outcomes for BMs.
